Can Natural Products Exert Neuroprotection without Crossing the Blood–Brain Barrier?
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
The scope of evidence on the neuroprotective impact of natural products has been greatly extended in recent years. However, a key question that remains to be answered is whether natural products act directly on targets located in the central nervous system (CNS), or whether they act indirectly through other mechanisms in the periphery. While molecules utilized for brain diseases are typically bestowed with a capacity to cross the blood–brain barrier, it has been recently uncovered that peripheral metabolism impacts brain functions, including cognition. The gut–microbiota–brain axis is receiving increasing attention as another indirect pathway for orally administered compounds to act on the CNS. In this review, we will briefly explore these possibilities focusing on two classes of natural products: omega-3 polyunsaturated fatty acids (n-3 PUFAs) from marine sources and polyphenols from plants. The former will be used as an example of a natural product with relatively high brain bioavailability but with tightly regulated transport and metabolism, and the latter as an example of natural compounds with low brain bioavailability, yet with a growing amount of preclinical and clinical evidence of efficacy. In conclusion, it is proposed that bioavailability data should be sought early in the development of natural products to help identifying relevant mechanisms and potential impact on prevalent CNS disorders, such as Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedCryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312 · cited 5×
“It is increasingly recognized that cells forming the BBB can generate Aβ, but more importantly regulate its clearance out of the brain to the blood [192,202].”
BackgroundInfluentialDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
A molecular atlas of cell types and zonation in the brain vasculature
Vanlandewijck, M., He, L., Mäe, M. A., Andrae, J., Ando, K., Del Gaudio, F., Nahar, K., Lebouvier, T., Laviña, B., Gouveia, L., et al. (2018) · Nature · doi:10.1038/nature25739 · Cited by 1,892 · cited 2×
“BCECs express numerous influx and efflux transport systems that adjust the concentrations of endogenous molecules on both sides of the BBB [179,192,195,196].”
BackgroundKim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258
Williamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246
Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease
Kivipelto, M., Mangialasche, F., & Ngandu, T. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0070-3 · Cited by 1,173
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
Mechanisms of action of docosahexaenoic acid in the nervous system
Salem, N., Litman, B., Kim, H., & Gawrisch, K. (2001) · Lipids · doi:10.1007/s11745-001-0805-6 · Cited by 919
Andrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders
Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.013 · Cited by 718
Chatterjee, S., Peters, S. A. E., Woodward, M., Mejia Arango, S., Batty, G. D., Beckett, N., Beiser, A., Borenstein, A. R., Crane, P. K., Haan, M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1588 · Cited by 711
Phase II and phase III failures: 2013–2015
Harrison, R. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.184 · Cited by 636
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619
Nutrition and prevention of cognitive impairment
Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30338-7 · Cited by 612
Vagal pathways for microbiome-brain-gut axis communication
Forsythe, P., Bienenstock, J., & Kunze, W. A. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-0897-4_5 · Cited by 576 · cited 1×
“Of note, the gut is innervated by the enteric nervous system (ENS), which is connected to the brain through vagal pathways, thereby providing a direct neural link between diet, the gastrointestinal tract, its microbiota and the brain [226,227].”
BackgroundWorld‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia
Kivipelto, M., Mangialasche, F., Snyder, H. M., Allegri, R., Andrieu, S., Arai, H., Baker, L., Belleville, S., Brodaty, H., Brucki, S. M., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12123 · Cited by 553
Metabolic fate of polyphenols in the human superorganism
van Duynhoven, J., Vaughan, E. E., Jacobs, D. M., A. Kemperman, R., van Velzen, E. J. J., Gross, G., Roger, L. C., Possemiers, S., Smilde, A. K., Doré, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000098107 · Cited by 540 · cited 1×
“Their chemical structure is considerably altered by the wide enzymatic repertoire of the intestinal bacteria, involving ring-fission and cleavage reactions of functional groups [119].”
BackgroundRAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain
Kisler, K., Nelson, A. R., Rege, S. V., Ramanathan, A., Wang, Y., Ahuja, A., Lazic, D., Tsai, P. S., Zhao, Z., Zhou, Y., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4489 · Cited by 497
Hollman, P. C. H., Cassidy, A., Comte, B., Heinonen, M., Richelle, M., Richling, E., Serafini, M., Scalbert, A., Sies, H., & Vidry, S. (2011) · The Journal of Nutrition · doi:10.3945/jn.110.131490 · Cited by 406 · cited 1×
“It used to be assumed that polyphenols exerted their action through an antioxidant action, but this has been challenged, as very high concentration at the target sites would be necessary [75,112,122,228].”
BackgroundBlood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405 · cited 3×
“Finally, cerebrospinal fluid (CSF) levels are still used as a surrogate marker of brain penetration, while it has been known for a long time that many compounds transit from the blood to the CSF without entering the brain per se [3,131,140].”
Backgroundde la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Drug transport in brain via the cerebrospinal fluid.
Pardridge, W. M. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-7 · Cited by 316 · cited 1×
“Finally, cerebrospinal fluid (CSF) levels are still used as a surrogate marker of brain penetration, while it has been known for a long time that many compounds transit from the blood to the CSF without entering the brain per se [3,131,140].”
BackgroundThe Translational Significance of the Neurovascular Unit
McConnell, H. L., Kersch, C. N., Woltjer, R. L., & Neuwelt, E. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.760215 · Cited by 314
Desideri, G., Kwik-Uribe, C., Grassi, D., Necozione, S., Ghiadoni, L., Mastroiacovo, D., Raffaele, A., Ferri, L., Bocale, R., Lechiara, M. C., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.193060 · Cited by 311 · cited 1×
“Therefore, the reported effect of polyphenols, such as cocoa flavonoids, on blood pressure provides a compelling example of such a mechanism not involving a direct CNS action [76,81,82,95,155,156].”
BackgroundCerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299 · cited 1×
“Reduced cerebral blood flow is one of the common early features of AD [157,158].”
BackgroundpH gradients across phospholipid membranes caused by fast flip-flop of un-ionized fatty acids.
Kamp, F., & Hamilton, J. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.23.11367 · Cited by 299 · cited 1×
“This comes as no surprise to the eyes of a neuropharmacologist, as the chemical structure of fatty acids (FAs) suggests free diffusion across lipid membranes forming the BBB [35,48,64].”
BackgroundAccumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats
Ishisaka, A., Ichikawa, S., Sakakibara, H., Piskula, M. K., Nakamura, T., Kato, Y., Ito, M., Miyamoto, K.-I., Tsuji, A., Kawai, Y., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.017 · Cited by 293
Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00115-7 · Cited by 288 · cited 1×
“Metabolic disorders are also associated with other CNS disorders such as schizophrenia [186,187] or PD [188–190] and/or their symptomatic treatment.”
BackgroundHigh-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Émond, V., Julien, P., & Calon, F. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.022 · Cited by 288
Self-citationCirculating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies
van der Lee, S. J., Teunissen, C. E., Pool, R., Shipley, M. J., Teumer, A., Chouraki, V., Melo van Lent, D., Tynkkynen, J., Fischer, K., Hernesniemi, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.012 · Cited by 197
An update on type 2 diabetes, vascular dementia and Alzheimer’s disease.
Exalto, L. G., Whitmer, R. A., Kappele, L. J., & Biessels, G. J. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.014 · Cited by 194
Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations
Schaffer, S., & Halliwell, B. (2012) · Genes & Nutrition · doi:10.1007/s12263-011-0255-5 · Cited by 178
Asllani, I., Habeck, C., Scarmeas, N., Borogovac, A., Brown, T. R., & Stern, Y. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600570 · Cited by 172 · cited 1×
“Reduced cerebral blood flow is one of the common early features of AD [157,158].”
BackgroundPardridge, W. M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1042364 · Cited by 159 · cited 1×
“BCECs express numerous influx and efflux transport systems that adjust the concentrations of endogenous molecules on both sides of the BBB [179,192,195,196].”
BackgroundDavies, M., Jones, R. D. O., Grime, K., Jansson-Löfmark, R., Fretland, A. J., Winiwarter, S., Morgan, P., & McGinnity, D. F. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.004 · Cited by 123 · cited 1×
“Bioavailability is quantitative, and its determination thus requires adequate analytic capabilities [1].”
BackgroundBespalov, A., Steckler, T., Altevogt, B., Koustova, E., Skolnick, P., Deaver, D., Millan, M. J., Bastlund, J. F., Doller, D., Witkin, J., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.88 · Cited by 84
Ettcheto, M., Cano, A., Manzine, P. R., Busquets, O., Verdaguer, E., Castro-Torres, R. D., García, M. L., Beas-Zarate, C., Olloquequi, J., Auladell, C., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01849-6 · Cited by 73
Fiocco, A. J., Krieger, L., D’Amico, D., Parrott, M. D., Laurin, D., Gaudreau, P., Greenwood, C., & Ferland, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.04.008 · Cited by 21
Cited by
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia
Connell, E., Le Gall, G., Pontifex, M. G., Sami, S., Cryan, J. F., Clarke, G., Müller, M., & Vauzour, D. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00548-6 · Cited by 208
Yan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5288698 · Cited by 97
Huang, R., Zhu, Z., Wu, Q., Bekhit, A. E.-D. A., Wu, S., Chen, M., Wang, J., & Ding, Y. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1975093 · Cited by 23
Metadata
- Authors
- Leclerc, M., Dudonné, S., & Calon, F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-03-25
- Volume
- 22
- Issue
- 7
- Pages
- 3356
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3139110815
- Cited by
- 47
- References
- 47
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.